SLC5A2 and diabetes mellitus: Two classes of anti-diabetic drugs, namely Sodium-Glucose co-Transporter-2 (SGLT-2) inhibitors and Glucagon-Like Peptide-1 (GLP-1) receptor agonists, have attracted scientific interest during the last decade due to their impressive cardiovascular beneficial effects in patients with DM [9-12].